These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 3130534

  • 1. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y, Kikuchi T, Suzuki S, Tsutsui M, Yamada K, Hiyama T.
    Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
    [Abstract] [Full Text] [Related]

  • 2. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S.
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [Abstract] [Full Text] [Related]

  • 3. Effect of 7-(3-[4-(2,3-dimethylphenyl)piperazinyl]propoxy)- 2(1H)-quinolinone (OPC-4392), a newly synthesized agonist for presynaptic dopamine D2 receptor, on tyrosine hydroxylation in rat striatal slices.
    Kiuchi K, Hirata Y, Minami M, Nagatsu T.
    Life Sci; 1988 Jul; 42(3):343-9. PubMed ID: 2892110
    [Abstract] [Full Text] [Related]

  • 4. Interactions of 7-[3-(4-[2,3-dimethylphenyl]piperazinyl)-propoxy]-2(1H)-quinolinone binding in rat striatum: effects of lesions.
    Zhang X, Nakata Y, Kikuchi T, Segawa T.
    Pharm Res; 1990 Mar; 7(3):280-2. PubMed ID: 1971105
    [Abstract] [Full Text] [Related]

  • 5. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
    Oshiro Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwahodo Y, Nishi T.
    J Med Chem; 1998 Feb 26; 41(5):658-67. PubMed ID: 9513593
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE, Haubrich DR, Williams M.
    Eur J Pharmacol; 1981 Nov 19; 76(1):15-23. PubMed ID: 7318920
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
    Neal BS, Joyce JN.
    Brain Res Dev Brain Res; 1991 Jun 21; 60(2):105-13. PubMed ID: 1832593
    [Abstract] [Full Text] [Related]

  • 10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 21; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA, Christofferson CL, Corbin A, DeWald HA, Demattos S, Meltzer LT, Myers SL, Shih YH, Whetzel SZ, Wiley JN.
    J Pharmacol Exp Ther; 1992 Dec 21; 263(3):1147-58. PubMed ID: 1361570
    [Abstract] [Full Text] [Related]

  • 12. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Dec 21; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 13. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J.
    Eur J Pharmacol; 1985 Jul 11; 113(1):79-88. PubMed ID: 2931283
    [Abstract] [Full Text] [Related]

  • 14. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M.
    Mol Pharmacol; 1987 Jun 11; 31(6):592-8. PubMed ID: 2885734
    [Abstract] [Full Text] [Related]

  • 15. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.
    Mulder AH, Draper R, Sminia P, Schoffelmeer AN, Stoof JC.
    Eur J Pharmacol; 1985 Jan 08; 107(3):291-7. PubMed ID: 3979429
    [Abstract] [Full Text] [Related]

  • 16. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
    Arnt J, Hyttel J.
    J Neural Transm; 1984 Jan 08; 60(3-4):205-23. PubMed ID: 6441835
    [Abstract] [Full Text] [Related]

  • 17. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation.
    Oberlander C, Boissier JR.
    J Pharmacol; 1983 Jan 08; 14(4):401-4. PubMed ID: 6423905
    [Abstract] [Full Text] [Related]

  • 18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D, Salah RS, Galloway MP.
    Synapse; 1991 Jul 08; 8(3):169-76. PubMed ID: 1948667
    [Abstract] [Full Text] [Related]

  • 19. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
    Hársing LG, Vizi ES.
    Pol J Pharmacol Pharm; 1985 Jul 08; 37(3):383-96. PubMed ID: 2866504
    [Abstract] [Full Text] [Related]

  • 20. Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses.
    Herrera-Marschitz M, Casas M, Ungerstedt U.
    Psychopharmacology (Berl); 1988 Jul 08; 94(1):38-45. PubMed ID: 3126526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.